#BEGIN_DRUGCARD DB02555

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C33H42Cl2N8O4

# Chemical_IUPAC_Name:
(2R)-2-[(diaminomethylidene)amino]-N-{2-[4-(3-{2,3-dichloro-4-[(4-acetamidophenyl)methoxy]phenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-4-methylpentanamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
SP4160

# HET_ID:
FRI

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C33H42Cl2N8O4/c1-19(2)15-26(40-33(36)37)32(46)38-17-29(45)43-13-11-22(12-14-43)27-16-25(41-42(27)4)24-9-10-28(31(35)30(24)34)47-18-21-5-7-23(8-6-21)39-20(3)44/h5-10,16,19,22,26H,11-15,17-18H2,1-4H3,(H,38,46)(H,39,44)(H4,36,37,40)/t26-/m1/s1

# InChI_Key:
InChIKey=VCXMTWSYQSVWRK-AREMUKBSSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2555

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
685.644

# Molecular_Weight_Mono:
684.270607286

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1QVN

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
4.72

# Predicted_LogS:
-5

# Predicted_Water_Solubility:
6.16e-03 g/l

# Primary_Accession_No:
DB02555

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
656989

# PubChem_Substance_ID:
46506770

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01492

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)C[C@@H](N=C(N)N)C(=O)NCC(=O)N1CCC(CC1)C1=CC(=NN1C)C1=C(Cl)C(Cl)=C(OCC2=CC=C(NC(C)=O)C=C2)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:15 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
IL2

# Drug_Target_1_GenBank_ID_Gene:
J00264

# Drug_Target_1_GenBank_ID_Protein:
5729676

# Drug_Target_1_GeneCard_ID:
IL2

# Drug_Target_1_Gene_Name:
IL2

# Drug_Target_1_Gene_Sequence:
>462 bp
ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACAAACAGT
GCACCTACTTCAAGTTCTACAAAGAAAACACAGCTACAACTGGAGCATTTACTGCTGGAT
TTACAGATGATTTTGAATGGAATTAATAATTACAAGAATCCCAAACTCACCAGGATGCTC
ACATTTAAGTTTTACATGCCCAAGAAGGCCACAGAACTGAAACATCTTCAGTGTCTAGAA
GAAGAACTCAAACCTCTGGAGGAAGTGCTAAATTTAGCTCAAAGCAAAAACTTTCACTTA
AGACCCAGGGACTTAATCAGCAATATCAACGTAATAGTTCTGGAACTAAAGGGATCTGAA
ACAACATTCATGTGTGAATATGCTGATGAGACAGCAACCATTGTAGAATTTCTGAACAGA
TGGATTACCTTTTGTCAAAGCATCATCTCAACACTGACTTGA

# Drug_Target_1_General_Function:
Involved in interleukin-2 receptor binding

# Drug_Target_1_General_References:
1510960	Mott HR, Driscoll PC, Boyd J, Cooke RM, Weir MP, Campbell ID: Secondary structure of human interleukin 2 from 3D heteronuclear NMR experiments. Biochemistry. 1992 Aug 25;31(33):7741-4.
1631562	Bazan JF: Unraveling the structure of IL-2. Science. 1992 Jul 17;257(5068):410-3.
2793860	Conradt HS, Nimtz M, Dittmar KE, Lindenmaier W, Hoppe J, Hauser H: Expression of human interleukin-2 in recombinant baby hamster kidney, Ltk-, and Chinese hamster ovary cells. Structure of O-linked carbohydrate chains and their location within the polypeptide. J Biol Chem. 1989 Oct 15;264(29):17368-73.
3264184	Weir MP, Chaplin MA, Wallace DM, Dykes CW, Hobden AN: Structure-activity relationships of recombinant human interleukin 2. Biochemistry. 1988 Sep 6;27(18):6883-92.
3491296	Siebenlist U, Durand DB, Bressler P, Holbrook NJ, Norris CA, Kamoun M, Kant JA, Crabtree GR: Promoter region of interleukin-2 gene undergoes chromatin structure changes and confers inducibility on chloramphenicol acetyltransferase gene during activation of T cells. Mol Cell Biol. 1986 Sep;6(9):3042-9.
3500515	Brandhuber BJ, Boone T, Kenney WC, McKay DB: Three-dimensional structure of interleukin-2. Science. 1987 Dec 18;238(4834):1707-9.
6306584	Devos R, Plaetinck G, Cheroutre H, Simons G, Degrave W, Tavernier J, Remaut E, Fiers W: Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucleic Acids Res. 1983 Jul 11;11(13):4307-23.
6312994	Maeda S, Nishino N, Obaru K, Mita S, Nomiyama H, Shimada K, Fujimoto K, Teranishi T, Hirano T, Onoue K: Cloning of interleukin 2 mRNAs from human tonsils. Biochem Biophys Res Commun. 1983 Sep 30;115(3):1040-7.
6324170	Fujita T, Takaoka C, Matsui H, Taniguchi T: Structure of the human interleukin 2 gene. Proc Natl Acad Sci U S A. 1983 Dec;80(24):7437-41.
6330695	Holbrook NJ, Lieber M, Crabtree GR: DNA sequence of the 5' flanking region of the human interleukin 2 gene: homologies with adult T-cell leukemia virus. Nucleic Acids Res. 1984 Jun 25;12(12):5005-13.
6333684	Robb RJ, Kutny RM, Panico M, Morris HR, Chowdhry V: Amino acid sequence and post-translational modification of human interleukin 2. Proc Natl Acad Sci U S A. 1984 Oct;81(20):6486-90.
6403867	Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R, Hamuro J: Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983 Mar 24-30;302(5906):305-10.
6608729	Holbrook NJ, Smith KA, Fornace AJ Jr, Comeau CM, Wiskocil RL, Crabtree GR: T-cell growth factor: complete nucleotide sequence and organization of the gene in normal and malignant cells. Proc Natl Acad Sci U S A. 1984 Mar;81(6):1634-8.
7529123	Bamborough P, Hedgecock CJ, Richards WG: The interleukin-2 and interleukin-4 receptors studied by molecular modelling. Structure. 1994 Sep 15;2(9):839-51.
7722480	Eizenberg O, Faber-Elman A, Lotan M, Schwartz M: Interleukin-2 transcripts in human and rodent brains: possible expression by astrocytes. J Neurochem. 1995 May;64(5):1928-36.
8824916	Chernicky CL, Tan H, Burfeind P, Ilan J, Ilan J: Sequence of interleukin-2 isolated from human placental poly A+ RNA: possible role in maintenance of fetal allograft. Mol Reprod Dev. 1996 Feb;43(2):180-6.

# Drug_Target_1_HGNC_ID:
HGNC:6001

# Drug_Target_1_HPRD_ID:
00979

# Drug_Target_1_ID:
1575

# Drug_Target_1_Locus:
4q26-q27

# Drug_Target_1_Molecular_Weight:
17628

# Drug_Target_1_Name:
Interleukin-2

# Drug_Target_1_Number_of_Residues:
153

# Drug_Target_1_PDB_ID:
1PW6

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00715	IL2

# Drug_Target_1_Protein_Sequence:
>Interleukin-2 precursor
MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRML
TFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE
TTFMCEYADETATIVEFLNRWITFCQSIISTLT

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-20

# Drug_Target_1_Specific_Function:
Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine- activated killer cells, natural killer cells, and glioma cells

# Drug_Target_1_SwissProt_ID:
P60568

# Drug_Target_1_SwissProt_Name:
IL2_HUMAN

# Drug_Target_1_Synonyms:
Aldesleukin
IL-2
Interleukin-2 precursor
T-cell growth factor
TCGF

# Drug_Target_1_Theoretical_pI:
7.95

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB02555
